Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00630331 · ClinicalTrials.gov registry record · Phase 3
Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects
A Phase 3 study of Influenza, sponsored by Novartis Vaccines.
- Completed
- Registry status
- Phase 3
- Development phase
- 11,404
- Enrollment target
- 20
- Study locations
NCT00630331: Completed Phase 3 study of Influenza, sponsored by Novartis Vaccines.
NCT00630331 is a Phase 3 study of Influenza that has completed, run by Novartis Vaccines. The registered enrollment target is 11,404 participants, below the 36,731-participant average among 156 other Influenza trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00630331, a Phase 3 study of Influenza, has completed, sponsored by Novartis Vaccines.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 11,404 participants
- Enrollment target
- 20
- Study locations
Study Summary
The present study will evaluate clinical efficacy, safety, tolerability and immunogenicity of both Novartis Vaccines' cell-derived influenza vaccine and egg-derived influenza vaccine in healthy adults 18 to 49 years of age.
Primary Outcome
The vaccine efficacy of CCI and IVV vaccines was estimated relative to Placebo group as the number of subjects prevented against virus-confirmed symptomatic influenza illness caused by each of three vaccine-like virus strains.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Cell culture-derived influenza vaccine
- BIOLOGICAL Egg-derived influenza virus vaccine
Study Locations (20)
Other
- Site 25 - Espoo
- Site 26 - Helsinki
- Site 27 - Helsinki
Florida
- Site 15 - Pembroke Pines
- Site 17 - South Miami
New York
- Site 10 - Binghamton
- Site 5 - Endwell
Texas
- Site 9 - Austin
- Site 8 - Dallas
Utah
- Site 7 - Salt Lake City
- Site 3 - Salt Lake City
Colorado
- Site 14 - Denver
Kansas
- Site 13 - Lenexa
Kentucky
- Site 2 - Bardstown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,404 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
What the finished NCT00630331 record still lists
NCT00630331 is an interventional study that assigns participants to a tested intervention. Its 11,404 participants enrollment target places it among the larger protocols in the corpus, below the 36,731-participant average among 156 other Influenza trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00630331 names 20 study sites across 14 states, led by Other, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT00630331 about?
NCT00630331 is a clinical study titled "Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects". The present study will evaluate clinical efficacy, safety, tolerability and immunogenicity of both Novartis Vaccines' cell-derived influenza vaccine and egg-derived influenza vaccine in healthy adults 18 to 49 years of age.
What is the current status of trial NCT00630331?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 11,404 participants. The study started on 2007-10. Estimated completion is 2008-07.
What conditions does trial NCT00630331 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT00630331?
The interventions under investigation include: Placebo (BIOLOGICAL), Cell culture-derived influenza vaccine (BIOLOGICAL), Egg-derived influenza virus vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00630331?
This trial is sponsored by Novartis Vaccines, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00630331 being conducted?
This trial has 20 study locations across Colorado, Florida, Kansas, Kentucky, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00630331's enrollment target sits among peer trials
11,404 11th of 156 higher than 146 of 156 other Influenza trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts
RECRUITING · Phase 3
-
A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza
ACTIVE NOT RECRUITING · Phase 3
-
Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years
COMPLETED · Phase 3
-
Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age
COMPLETED · Phase 3
-
Study of Quadrivalent Influenza Vaccine Among Children
COMPLETED · Phase 3
-
Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06677060 · 11,300 participants · Phase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
- NCT07064473 · 11,800 participants · Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
- NCT06531824 · 11,000 participants · Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
- NCT07136012 · 11,000 participants · Phase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia